Published in N Engl J Med on October 12, 2000
Preservation of fertility in patients with cancer. N Engl J Med (2009) 7.11
Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer (2008) 2.63
Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis. JAMA Oncol (2016) 2.47
NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw (2009) 1.97
Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol Drug Saf (2013) 1.28
Cancer screening and preventative care among long-term cancer survivors in the United Kingdom. Br J Cancer (2010) 1.22
Caring for survivors of breast cancer: perspective of the primary care physician. Curr Oncol (2011) 1.11
Evaluation of the Quality of Life in Adult Cancer Survivors (QLACS) scale for long-term cancer survivors in a sample of breast cancer survivors. Health Qual Life Outcomes (2006) 1.10
Premature menopause in young breast cancer: effects on quality of life and treatment interventions. J Thorac Dis (2013) 0.95
Longitudinal patterns in survival, comorbidity, healthcare utilization and quality of care among older women following breast cancer diagnosis. J Gen Intern Med (2010) 0.93
A randomized trial of exercise on well-being and function following breast cancer surgery: the RESTORE trial. J Cancer Surviv (2011) 0.92
Incorporating fertility preservation into the care of young oncology patients. Cancer (2011) 0.90
Area-level poverty is associated with greater risk of ambulatory-care-sensitive hospitalizations in older breast cancer survivors. J Am Geriatr Soc (2008) 0.89
Adherence to hormone therapy among women with breast cancer. BMC Cancer (2014) 0.89
Medical and psychosocial aspects of fertility after cancer. Cancer J (2009) 0.89
Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient. J Cancer Res Clin Oncol (2006) 0.87
The impact of primary care physicians on follow-up care of underserved breast cancer survivors. J Am Board Fam Med (2013) 0.87
Morbidity after conventional dissection of axillary lymph nodes in breast cancer patients. World J Surg Oncol (2014) 0.83
Occurrence of fatigue and associated factors in disease-free breast cancer patients without depression. Support Care Cancer (2005) 0.81
Racial disparities in healthy behaviors and cancer screening among breast cancer survivors and women without cancer: National Health Interview Survey 2005. Cancer Causes Control (2014) 0.80
The reality in the follow-up of breast cancer survivors: survey of Korean Breast Cancer Society. Ann Surg Treat Res (2015) 0.79
Exploring the use of the survivorship consult in providing survivorship care. Support Care Cancer (2013) 0.78
The reality in the surveillance of breast cancer survivors-results of a patient survey. Breast Cancer (Auckl) (2008) 0.78
Models of care for early-stage breast cancer in Canada. Curr Oncol (2011) 0.77
Survivors of breast cancer. N Engl J Med (2001) 0.75
The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy induced ovarian failure in patient with gynecological malignancies. Obstet Gynecol Sci (2014) 0.75
Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer. PLoS One (2016) 0.75
Chemotherapy-induced cardiomyopathy in breast cancer patients. Res Cardiovasc Med (2014) 0.75
Survivors of breast cancer. N Engl J Med (2001) 0.75
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol (1999) 4.12
Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol (2001) 3.23
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol (1998) 2.55
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol (1999) 2.03
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol (2001) 1.89
Weight gain in women diagnosed with breast cancer. J Am Diet Assoc (1997) 1.87
Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr (2001) 1.84
Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol (1998) 1.66
Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol (2000) 1.41
Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Am J Clin Nutr (1997) 1.37
Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer (1998) 1.34
Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat (2011) 1.29
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol (2005) 1.25
Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol (2013) 1.24
NCCN Practice Guidelines for Breast Cancer. Oncology (Williston Park) (2000) 1.22
Why women gain weight with adjuvant chemotherapy for breast cancer. J Clin Oncol (1993) 1.21
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat (2009) 1.19
Menopausal-type symptoms in young breast cancer survivors. Ann Oncol (2006) 1.15
Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int J Radiat Oncol Biol Phys (1990) 1.06
Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. J Womens Health Gend Based Med (2001) 1.05
High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst (1992) 1.04
Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol (1999) 1.03
The impact of sharing results of a randomized breast cancer clinical trial with study participants. Breast Cancer Res Treat (2008) 1.03
Cancer pain survey: patient-centered issues in control. J Pain Symptom Manage (1998) 1.03
A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer (2000) 1.01
Attitudes of patients with metastatic breast cancer toward research biopsies. Ann Oncol (2013) 0.96
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol (2012) 0.94
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol (2011) 0.92
Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol (1999) 0.87
CMF revisited in the 21st century. Ann Oncol (2011) 0.85
Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J Clin Oncol (1999) 0.84
Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. Cancer Res (1992) 0.84
New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol (2001) 0.84
Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Ann Oncol (2012) 0.83
Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol (2000) 0.83
Liposomal anthracyclines for breast cancer. Semin Oncol (2001) 0.82
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. J Clin Oncol (1999) 0.82
Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Ann Surg Oncol (2010) 0.82
Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial. Cancer Chemother Pharmacol (1997) 0.82
Quality of life issues among women undergoing high-dose chemotherapy for breast cancer. Breast Dis (2001) 0.81
Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol (1994) 0.80
A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol (2013) 0.80
Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making (1999) 0.80
Patient Motivation, Satisfaction, and Coping in Genetic Counseling and Testing for BRCA1 and BRCA2. J Genet Couns (2000) 0.80
A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat (2013) 0.79
Overestimation of hereditary breast cancer risk. Ann Surg (1998) 0.78
Testing for hereditary breast and ovarian cancer in the southeastern United States. Ann Surg (2000) 0.78
Oral 5-FU analogues in the treatment of breast cancer. Oncology (Williston Park) (1998) 0.78
Factors contributing to patient satisfaction with breast reconstruction using silicone gel implants. Plast Reconstr Surg (1996) 0.77
A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer. Breast Cancer Res Treat (2013) 0.76
Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. J Infus Chemother (1996) 0.75
The use of adjuvant chemotherapy for breast cancer in a community practice. Conn Med (1985) 0.75
A review of hereditary breast cancer: from screening to risk factor modification. Am J Med (1997) 0.75
Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer. Cancer Chemother Pharmacol (1999) 0.75